Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

Manlio Mencoboni, Rosa A Filiberti, Paola Taveggia, Federica Grosso, Giulia Pasello, Lisette Del Corso, Alberto Muzio, Valentina Polo, Paolo Zucali, Giovanni L Ceresoli, Hector J Soto Parra, Laura Auriati, Claudio Simonassi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments.METHODS: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated.RESULTS: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p <0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005).CONCLUSION: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.
Original languageEnglish
Pages (from-to)364-369
Number of pages6
JournalOncology Research and Treatment
Volume40
Issue number6
DOIs
Publication statusPublished - 2017

Fingerprint

Pemetrexed
Drug Therapy
Therapeutics
Mesothelioma
Malignant Mesothelioma
Survival
Disease-Free Survival
Radiotherapy
Demography
Pharmaceutical Preparations

Keywords

  • Journal Article

Cite this

Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. / Mencoboni, Manlio; Filiberti, Rosa A; Taveggia, Paola; Grosso, Federica; Pasello, Giulia; Del Corso, Lisette; Muzio, Alberto; Polo, Valentina; Zucali, Paolo; Ceresoli, Giovanni L; Soto Parra, Hector J; Auriati, Laura; Simonassi, Claudio.

In: Oncology Research and Treatment, Vol. 40, No. 6, 2017, p. 364-369.

Research output: Contribution to journalArticle

Mencoboni, M, Filiberti, RA, Taveggia, P, Grosso, F, Pasello, G, Del Corso, L, Muzio, A, Polo, V, Zucali, P, Ceresoli, GL, Soto Parra, HJ, Auriati, L & Simonassi, C 2017, 'Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma', Oncology Research and Treatment, vol. 40, no. 6, pp. 364-369. https://doi.org/10.1159/000464410
Mencoboni, Manlio ; Filiberti, Rosa A ; Taveggia, Paola ; Grosso, Federica ; Pasello, Giulia ; Del Corso, Lisette ; Muzio, Alberto ; Polo, Valentina ; Zucali, Paolo ; Ceresoli, Giovanni L ; Soto Parra, Hector J ; Auriati, Laura ; Simonassi, Claudio. / Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma. In: Oncology Research and Treatment. 2017 ; Vol. 40, No. 6. pp. 364-369.
@article{41eeff8c585c4822a34a677f8931744c,
title = "Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma",
abstract = "BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments.METHODS: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated.RESULTS: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2{\%} of patients (75.7{\%} in patients treated with pemetrexed combined with other drugs and 69{\%} with pemetrexed as monotherapy). The disease control rate was 82.6{\%} in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p <0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005).CONCLUSION: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.",
keywords = "Journal Article",
author = "Manlio Mencoboni and Filiberti, {Rosa A} and Paola Taveggia and Federica Grosso and Giulia Pasello and {Del Corso}, Lisette and Alberto Muzio and Valentina Polo and Paolo Zucali and Ceresoli, {Giovanni L} and {Soto Parra}, {Hector J} and Laura Auriati and Claudio Simonassi",
note = "{\circledC} 2017 S. Karger GmbH, Freiburg.",
year = "2017",
doi = "10.1159/000464410",
language = "English",
volume = "40",
pages = "364--369",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

AU - Mencoboni, Manlio

AU - Filiberti, Rosa A

AU - Taveggia, Paola

AU - Grosso, Federica

AU - Pasello, Giulia

AU - Del Corso, Lisette

AU - Muzio, Alberto

AU - Polo, Valentina

AU - Zucali, Paolo

AU - Ceresoli, Giovanni L

AU - Soto Parra, Hector J

AU - Auriati, Laura

AU - Simonassi, Claudio

N1 - © 2017 S. Karger GmbH, Freiburg.

PY - 2017

Y1 - 2017

N2 - BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments.METHODS: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated.RESULTS: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p <0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005).CONCLUSION: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

AB - BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments.METHODS: Demographic and clinical data were collected. Treatment was assessed in terms of chemotherapy (line of treatment, pemetrexed-based regimen, other therapies), surgery, and radiotherapy. Response to therapy, progression-free survival, and overall survival were evaluated.RESULTS: 36 and 342 patients received best supportive care and active treatment, respectively; 86 patients underwent surgery, and 26 received trimodal therapy. Disease control after first-line chemotherapy was achieved in 74.2% of patients (75.7% in patients treated with pemetrexed combined with other drugs and 69% with pemetrexed as monotherapy). The disease control rate was 82.6% in pemetrexed re-challenged individuals. Median survival time was 11.6 months with supportive care, 16.2 months with chemotherapy only, 32.4 months with surgery plus chemotherapy, and 47.2 months with trimodal therapy. A more favorable prognosis was observed in responders to first-line therapy who were then actively treated with second-line (24.8 vs. 11.8 months in non-responders, p <0.001) and third-line chemotherapy (28.9 vs. 17.8 months in non-responders, p = 0.005).CONCLUSION: Mesothelioma patients benefited from chemotherapy alone only when retreated in the second line after response to first-line therapy.

KW - Journal Article

U2 - 10.1159/000464410

DO - 10.1159/000464410

M3 - Article

VL - 40

SP - 364

EP - 369

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 6

ER -